Candriam S.C.A. Genmab A/S Transaction History

Candriam S.C.A.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$34.88 - $43.22 $64,423 - $79,827	-1,847 Reduced 1.71%	106,291 $4.01 Million
Q4 2022 Feb 13, 2023	SELL	$33.8 - $47.06 $485,807 - $676,393	-14,373 Reduced 11.73%	108,138 $4.58 Million
Q3 2022 Nov 10, 2022	BUY	$31.52 - $373.61 $65,782 - $779,724	2,087 Added 1.73%	122,511 $3.94 Million
Q2 2022 Aug 03, 2022	SELL	$26.83 - $38.57 $992,119 - $1.43 Million	-36,978 Reduced 23.49%	120,424 $3.91 Million
Q1 2022 May 13, 2022	BUY	$30.95 - $39.68 $585,388 - $750,507	18,914 Added 13.66%	157,402 $5.69 Million
Q4 2021 Feb 10, 2022	BUY	$35.87 - $47.12 $73,174 - $96,124	2,040 Added 1.5%	138,488 $5.48 Million
Q3 2021 Nov 09, 2021	BUY	$41.55 - $48.72 $5.66 Million - $6.64 Million	136,312 Added 100229.41%	136,448 $5.96 Million
Q2 2021 Jul 20, 2021	SELL	$32.88 - $44.57 $2.51 Million - $3.4 Million	-76,313 Reduced 99.82%	136 $6,000
Q1 2021 Apr 29, 2021	BUY	$30.92 - $44.4 $2,071 - $2,974	67 Added 0.09%	76,449 $2.99 Million
Q4 2020 Jan 22, 2021	SELL	$33.66 - $40.76 $2.6 Million - $3.15 Million	-77,181 Reduced 50.26%	76,382 $3.11 Million
Q3 2020 Oct 19, 2020	BUY	$33.07 - $38.68 $235,888 - $275,904	7,133 Added 4.87%	153,563 $5.62 Million
Q2 2020 Jul 23, 2020	SELL	$20.05 - $33.89 $930,961 - $1.57 Million	-46,432 Reduced 24.08%	146,430 $4.96 Million
Q1 2020 May 26, 2020	BUY	$17.15 - $25.22 $4,116 - $6,052	240 Added 0.12%	192,862 $4.21 Million
Q4 2019 Jan 21, 2020	BUY	$18.88 - $24.14 $3.64 Million - $4.65 Million	192,622 New	192,622 $4,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.